Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, IGC Pharma Inc’s stock clocked out at $0.28, down -0.39% from its previous closing price of $0.28. In other words, the price has decreased by -$0.39 from its previous closing price. On the day, 0.56 million shares were traded. IGC stock price reached its highest trading level at $0.2848 during the session, while it also had its lowest trading level at $0.275.
Ratios:
To gain a deeper understanding of IGC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.87 and its Current Ratio is at 1.32. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IGC now has a Market Capitalization of 26133122 and an Enterprise Value of 25149124. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.54 while its Price-to-Book (P/B) ratio in mrq is 3.20. Its current Enterprise Value per Revenue stands at 22.739 whereas that against EBITDA is -3.343.
Stock Price History:
The Beta on a monthly basis for IGC is 0.32, which has changed by -0.22222221 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, IGC has reached a high of $0.50, while it has fallen to a 52-week low of $0.25. The 50-Day Moving Average of the stock is -17.79%, while the 200-Day Moving Average is calculated to be -18.25%.
Shares Statistics:
It appears that IGC traded 811.85K shares on average per day over the past three months and 1161440 shares per day over the past ten days. A total of 91.96M shares are outstanding, with a floating share count of 71.51M. Insiders hold about 23.00% of the company’s shares, while institutions hold 5.86% stake in the company. Shares short for IGC as of 1765756800 were 428376 with a Short Ratio of 0.53, compared to 1763078400 on 244156. Therefore, it implies a Short% of Shares Outstanding of 428376 and a Short% of Float of 0.61000003.
Earnings Estimates
At present, 2.0 analysts are actively evaluating the performance of IGC Pharma Inc (IGC) in the stock market.The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.08 and -$0.08 for the fiscal current year, implying an average EPS of -$0.08. EPS for the following year is -$0.09, with 2.0 analysts recommending between -$0.09 and -$0.09.
Revenue Estimates
In. The current quarter, 1 analysts expect revenue to total $193k. It ranges from a high estimate of $193k to a low estimate of $193k. As of. The current estimate, IGC Pharma Inc’s year-ago sales were $257kFor the next quarter, 1 analysts are estimating revenue of $198k. There is a high estimate of $198k for the next quarter, whereas the lowest estimate is $198k.
A total of 1 analysts have provided revenue estimates for IGC’s current fiscal year. The highest revenue estimate was $910k, while the lowest revenue estimate was $910k, resulting in an average revenue estimate of $910k. In the same quarter a year ago, actual revenue was $1.27MBased on 2 analysts’ estimates, the company’s revenue will be $1.25M in the next fiscal year. The high estimate is $1.5M and the low estimate is $1M.
